Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 0.79
(-5.94%)
SEK 0.79
(-5.94%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -55.41 Million SEK | -17.55% |
| 2022 | -47.14 Million SEK | -330.25% |
| 2021 | -10.95 Million SEK | 76.0% |
| 2020 | -45.65 Million SEK | -8.37% |
| 2019 | -42.12 Million SEK | -10.45% |
| 2018 | -38.14 Million SEK | -61.75% |
| 2017 | -23.58 Million SEK | -38.18% |
| 2016 | -17.06 Million SEK | -39.42% |
| 2015 | -12.24 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -29.3 Million SEK | -94.16% |
| 2023 Q3 | -13.65 Million SEK | 53.4% |
| 2023 Q4 | -13.65 Million SEK | 0.0% |
| 2023 FY | -55.41 Million SEK | -17.55% |
| 2023 Q1 | -15.09 Million SEK | 33.68% |
| 2022 Q4 | -22.76 Million SEK | -98.22% |
| 2022 Q2 | -23.81 Million SEK | -96.98% |
| 2022 Q1 | -12.08 Million SEK | 44.84% |
| 2022 FY | -47.14 Million SEK | -330.25% |
| 2022 Q3 | -11.48 Million SEK | 51.78% |
| 2021 Q2 | -22.73 Million SEK | -591.25% |
| 2021 FY | -10.95 Million SEK | 76.0% |
| 2021 Q1 | 4.62 Million SEK | 137.71% |
| 2021 Q4 | -21.91 Million SEK | -116.83% |
| 2021 Q3 | -10.1 Million SEK | 55.54% |
| 2020 Q3 | -12.27 Million SEK | -28.6% |
| 2020 Q2 | -9.54 Million SEK | 17.38% |
| 2020 Q1 | -11.55 Million SEK | 47.03% |
| 2020 FY | -45.65 Million SEK | -8.37% |
| 2020 Q4 | -12.27 Million SEK | 0.0% |
| 2019 Q2 | -11.55 Million SEK | -11.23% |
| 2019 Q1 | -10.39 Million SEK | 52.28% |
| 2019 FY | -42.12 Million SEK | -10.45% |
| 2019 Q4 | -21.8 Million SEK | -92.68% |
| 2019 Q3 | -11.31 Million SEK | 2.07% |
| 2018 Q2 | -8.84 Million SEK | -20.66% |
| 2018 FY | -38.14 Million SEK | -61.75% |
| 2018 Q4 | -21.77 Million SEK | -175.09% |
| 2018 Q3 | -7.91 Million SEK | 10.54% |
| 2018 Q1 | -7.33 Million SEK | 20.78% |
| 2017 Q3 | -4.18 Million SEK | 23.2% |
| 2017 Q1 | -5.44 Million SEK | -2.95% |
| 2017 FY | -23.58 Million SEK | -38.18% |
| 2017 Q4 | -9.25 Million SEK | -121.41% |
| 2017 Q2 | -5.44 Million SEK | 0.0% |
| 2016 Q4 | -5.28 Million SEK | 0.0% |
| 2016 FY | -17.06 Million SEK | -39.42% |
| 2015 FY | -12.24 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 77.743% |
| Ziccum AB (publ) | -21.56 Million SEK | -157.036% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -237.888% |
| BioArctic AB (publ) | 252.64 Million SEK | 121.935% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -6458.225% |
| Mendus AB (publ) | -100.65 Million SEK | 44.941% |
| Genovis AB (publ.) | 54.22 Million SEK | 202.2% |
| Intervacc AB (publ) | -93.57 Million SEK | 40.781% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -257.252% |
| Active Biotech AB (publ) | -46.48 Million SEK | -19.217% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 407.718% |
| Aptahem AB (publ) | -10.1 Million SEK | -448.425% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 82.763% |
| Kancera AB (publ) | -65.04 Million SEK | 14.798% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 58.834% |
| Fluicell AB (publ) | -26.87 Million SEK | -106.172% |
| Saniona AB (publ) | -81.06 Million SEK | 31.639% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -347.959% |
| Biovica International AB (publ) | -126.07 Million SEK | 56.044% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -30.378% |
| AcouSort AB (publ) | -17.48 Million SEK | -216.904% |
| Xintela AB (publ) | -57.23 Million SEK | 3.181% |
| Abliva AB (publ) | -96.54 Million SEK | 42.602% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 82.938% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1481.084% |
| OncoZenge AB (publ) | -15.9 Million SEK | -248.491% |
| Amniotics AB (publ) | -29.07 Million SEK | -90.613% |
| 2cureX AB (publ) | -36.36 Million SEK | -52.399% |
| CombiGene AB (publ) | -36.3 Million SEK | -52.642% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -278.531% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 85.583% |
| Camurus AB (publ) | 532.35 Million SEK | 110.41% |
| Corline Biomedical AB | -1.78 Million SEK | -2999.385% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 69.343% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -32.949% |
| I-Tech AB | 24.43 Million SEK | 326.794% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 92.972% |
| Cyxone AB (publ) | -21.66 Million SEK | -155.838% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 47.703% |
| Biosergen AB | -27.26 Million SEK | -103.253% |
| Cantargia AB (publ) | -290.01 Million SEK | 80.892% |
| NextCell Pharma AB | -43.17 Million SEK | -28.363% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 69.343% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -224.147% |
| Nanologica AB (publ) | -69.96 Million SEK | 20.791% |
| SynAct Pharma AB | -224.49 Million SEK | 75.315% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -25.446% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -131.345% |
| LIDDS AB (publ) | -40.67 Million SEK | -36.247% |
| Lipum AB (publ) | -37.25 Million SEK | -48.754% |
| BioInvent International AB (publ) | -369.94 Million SEK | 85.02% |
| Alzinova AB (publ) | -16.52 Million SEK | -235.413% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 78.135% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -766.805% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 51.842% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -175.173% |
| Simris Alg AB (publ) | -36.63 Million SEK | -51.268% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 62.19% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 82.148% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 50.036% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -379.137% |